The EPO published patent application EP3931317A1 filed by Benitec IP Holdings Inc. relating to compositions and methods for treating Oculopharyngeal Muscular Dystrophy (OPMD), a rare genetic muscle disorder. The application covers therapeutic uses including gene therapy vectors and associated pharmaceutical compositions. The designated states include all 27 EU member states plus other EPC contracting states.

Patent publications do not impose compliance obligations on third parties. Companies developing therapies for OPMD or related neuromuscular conditions should review this publication to assess potential freedom-to-operate implications or opportunities for licensing. The patent, if granted, will provide Benitec with exclusive rights in the designated territories.